<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-title>Arthritis Research &#x00026; Therapy</journal-title><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">ar2606</article-id><article-id pub-id-type="pmid">19435465</article-id><article-id pub-id-type="doi">10.1186/ar2606</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>5HT<sub>2A </sub>polymorphism His452Tyr in a German Caucasian systemic sclerosis population</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Kirsten</surname><given-names>Holger</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>holger.kirsten@izi.fraunhofer.de</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Burkhardt</surname><given-names>Jana</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jana.burkhardt@medizin.uni-leipzig.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Hantmann</surname><given-names>Helene</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>helene.hantmann@izi.fraunhofer.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Hunzelmann</surname><given-names>Nico</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>nico.hunzelmann@uni-koeln.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Vaith</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>peter.vaith@uniklinik-freiburg.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Ahnert</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I6">6</xref><email>peter.ahnert@izi.fraunhofer.de</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Melchers</surname><given-names>Inga</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>Inga.melchers@uniklinik-freiburg.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Institute of Clinical Immunology and Transfusion Medicine, Center for Biotechnology and Biomedicine (BBZ), University of Leipzig, Johannisallee, 04103 Leipzig, Germany</aff><aff id="I2"><label>2</label>Fraunhofer Institute for Cell Therapy and Immunology, Perlickstr., 04103 Leipzig, Germany</aff><aff id="I3"><label>3</label>Translational Center for Regenerative Medicine, University of Leipzig, Phillip-Rosenthal-Str., 04103 Leipzig, Germany</aff><aff id="I4"><label>4</label>Department of Dermatology, University of Cologne, Kerpener Stra&#x000df;e, 50924 Cologne, Germany</aff><aff id="I5"><label>5</label>Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Hugstetter Str., 79106 Freiburg, Germany</aff><aff id="I6"><label>6</label>Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstr. 16-18, 04107 Leipzig, Germany</aff><aff id="I7"><label>7</label>Clinical Research Unit for Rheumatology, University Medical Center, Breisacher Str., 79106 Freiburg, Germany</aff><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>26</day><month>3</month><year>2009</year></pub-date><volume>11</volume><issue>2</issue><fpage>403</fpage><lpage>403</lpage><ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/11/2/403"/><permissions><copyright-statement>Copyright &#x000a9; 2009 BioMed Central Ltd</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>BioMed Central Ltd</copyright-holder></permissions></article-meta><notes><p>See related research by Beretta <italic>et al.</italic>, <ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/10/5/R103"/> and related letter by Beretta and Scorza, <ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/11/2/404"/></p></notes></front><body><sec><title/><p>Recently, Beretta and colleagues [<xref ref-type="bibr" rid="B1">1</xref>] reported a protective association of the serotonin 5-HT<sub>2A </sub>receptor gene polymorphism His452Tyr (C+1354T, rs6314) with systemic sclerosis (SSc) in an Italian population. 5HT<sub>2A </sub>accounts for most vasoconstrictive and platelet aggregation due to serotonin activity [<xref ref-type="bibr" rid="B2">2</xref>]. Beretta and colleagues also demonstrated that plasma from healthy heterozygous carriers of His452Tyr showed decreased platelet aggregation after serotonin stimulus compared to plasma from healthy individuals homozygous for His452. In consequence, they suggested a functional role of His452Tyr in reducing susceptibility to SSc.</p><p>We performed a population-based replication study in an independent and larger German Caucasian SSc cohort, approved by local ethics committees. DNA was purified from blood samples after obtaining written informed consent. Patients were included according to the German Network for Systemic Scleroderma guidelines [<xref ref-type="bibr" rid="B3">3</xref>]. The patient cohort was characterised as follows [<xref ref-type="bibr" rid="B4">4</xref>]: all fulfilled minimal requirements of LeRoy and colleagues [<xref ref-type="bibr" rid="B5">5</xref>] and 81% fulfilled ACR criteria [<xref ref-type="bibr" rid="B6">6</xref>]; 80% were females, 50% presented with the limited cutaneous form (lSSc [<xref ref-type="bibr" rid="B3">3</xref>]), 33% with the diffuse cutaneous form (dSSc [<xref ref-type="bibr" rid="B3">3</xref>]), 89% carried antinuclear antibodies (ANA-positive), 43% anticentromere antibodies (ACA-positive), 39% antitopoisomerase I antibodies (ATA-positive), and they had a mean age of disease onset of 49.5 &#x000b1; 13.8 years. Mass spectrometry-based genotyping was applied as described, with minor modifications [<xref ref-type="bibr" rid="B4">4</xref>]. Power was &#x0003e;96% to replicate the allelic association and &#x0003e;99% to replicate a decreased minor allele frequency within cases [<xref ref-type="bibr" rid="B7">7</xref>], as reported for the Italian population.</p><p>HapMap data reveal considerable variation of Tyr452 frequency among populations. It is especially high within Africans, emphasizing the importance of appropriate case-control matching. The frequency in our controls was very similar to that in the Caucasian HapMap cohort (0.065 versus 0.063, respectively). It was higher in the Italian population (0.124).</p><p>We did not find a protective association of His452Tyr with SSc. In contrast, the frequency of Tyr452 was not decreased, but even increased in all SSc patients (Table <xref ref-type="table" rid="T1">1</xref>). Also, no association was found when SSc subgroups stratified for the fulfilment of ACR-criteria, clinical classification (lSSc, dSSc), autoantibody status (ANA-, ACA-, ATA-positive) or sex were compared to healthy donors. However, Tyr452-positive SSc patients were less frequently dSSc positive than His452 homozygous SSc patients (<italic>P </italic>= 0.048, 9% versus 20%, respectively). This might indicate that the 5HT<sub>2A </sub>polymorphism may influence the severity of SSc.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Distribution of C+1354T within German systemic sclerosis patients and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="5">Genotype</td><td align="center" colspan="2">C versus T</td></tr><tr><td></td><td colspan="5"><hr></hr></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td align="center">CC</td><td align="center">CT</td><td align="center">TT</td><td align="center">Total</td><td align="center">MAF</td><td align="center">OR (95%CI)</td><td align="center"><italic>P</italic><sup>a</sup></td></tr></thead><tbody><tr><td align="left">Patients</td><td align="center">176</td><td align="center">31</td><td align="center">2</td><td align="center">209</td><td align="center">0.084</td><td align="center">1.32 (0.8&#x02013;2.2)</td><td align="center">0.28</td></tr><tr><td align="left">Controls</td><td align="center">203</td><td align="center">28</td><td align="center">1</td><td align="center">232</td><td align="center">0.065</td><td></td><td></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic>P</italic>-values were calculated with Fisher's exact test. Genotypes in cases and controls were consistent with Hardy-Weinberg equilibrium. Frequencies of genotypes were also not significantly different between patients and controls (<italic>P </italic>= 0.52, exact Fisher Freeman Halton test). CI, confidence interval; MAF, minor allele frequency; OR, odds ratio.</p></table-wrap-foot></table-wrap><p>In summary, we could not replicate an association of the 5HT<sub>2A </sub>His452Tyr polymorphism with SSc in a larger German Caucasian cohort. However, an influence of this single nucleotide polymorphism on severity of SSc may exist.</p></sec><sec><title>Abbreviations</title><p>SSc: systemic sclerosis.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Support originated from the BMBF ('German Network for Systemic Scleroderma' to IM and NH; 'Hochschul-Wissenschafts-Programm'to PA), the SAB (7692/1187) and EFRE (EFRE4212/04-04) to PA.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beretta</surname><given-names>L</given-names></name><name><surname>Cossu</surname><given-names>M</given-names></name><name><surname>Marchini</surname><given-names>M</given-names></name><name><surname>Cappiello</surname><given-names>F</given-names></name><name><surname>Artoni</surname><given-names>A</given-names></name><name><surname>Motta</surname><given-names>G</given-names></name><name><surname>Scorza</surname><given-names>R</given-names></name></person-group><article-title>A polymorphism in the human serotonin 5-HT<sub>2A </sub>receptor gene may protect against systemic sclerosis by reducing platelet aggregation</article-title><source>Arthritis Res Ther</source><year>2008</year><volume>10</volume><fpage>R103</fpage><pub-id pub-id-type="pmid">18761744</pub-id><pub-id pub-id-type="doi">10.1186/ar2495</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>DJ</given-names></name><name><surname>Harnett</surname><given-names>M</given-names></name><name><surname>MacLean</surname><given-names>M</given-names></name><name><surname>Peacock</surname><given-names>AJ</given-names></name></person-group><article-title>Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>170</volume><fpage>252</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">15087293</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200302-264OC</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunzelmann</surname><given-names>N</given-names></name><name><surname>Genth</surname><given-names>E</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name><name><surname>Lehmacher</surname><given-names>W</given-names></name><name><surname>Melchers</surname><given-names>I</given-names></name><name><surname>Meurer</surname><given-names>M</given-names></name><name><surname>Moinzadeh</surname><given-names>P</given-names></name><name><surname>M&#x000fc;ller-Ladner</surname><given-names>U</given-names></name><name><surname>Pfeiffer</surname><given-names>C</given-names></name><name><surname>Riemekasten</surname><given-names>G</given-names></name><name><surname>Schulze-Lohoff</surname><given-names>E</given-names></name><name><surname>Sunderkoetter</surname><given-names>C</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Worm</surname><given-names>M</given-names></name><name><surname>Klaus</surname><given-names>P</given-names></name><name><surname>Rubbert</surname><given-names>A</given-names></name><name><surname>Steinbrink</surname><given-names>K</given-names></name><name><surname>Grundt</surname><given-names>B</given-names></name><name><surname>Hein</surname><given-names>R</given-names></name><name><surname>Scharffetter-Kochanek</surname><given-names>K</given-names></name><name><surname>Hinrichs</surname><given-names>R</given-names></name><name><surname>Walker</surname><given-names>K</given-names></name><name><surname>Szeimies</surname><given-names>RM</given-names></name><name><surname>Karrer</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>A</given-names></name><name><surname>Seitz</surname><given-names>C</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Lehmann</surname><given-names>P</given-names></name><name><surname>Foeldv&#x000e1;ri</surname><given-names>I</given-names></name><name><surname>Reichenberger</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement</article-title><source>Rheumatology</source><year>2008</year><volume>47</volume><fpage>1185</fpage><lpage>1192</lpage><pub-id pub-id-type="pmid">18515867</pub-id><pub-id pub-id-type="doi">10.1093/rheumatology/ken179</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirsten</surname><given-names>H</given-names></name><name><surname>Blume</surname><given-names>M</given-names></name><name><surname>Emmrich</surname><given-names>F</given-names></name><name><surname>Hunzelmann</surname><given-names>N</given-names></name><name><surname>Mierau</surname><given-names>R</given-names></name><name><surname>Rzepka</surname><given-names>R</given-names></name><name><surname>Vaith</surname><given-names>P</given-names></name><name><surname>Witte</surname><given-names>T</given-names></name><name><surname>Melchers</surname><given-names>I</given-names></name><name><surname>Ahnert</surname><given-names>P</given-names></name></person-group><article-title>No association between systemic sclerosis and C77G polymorphism in the human PTPRC (CD45) gene</article-title><source>J Rheumatol</source><year>2008</year><volume>35</volume><fpage>1817</fpage><lpage>1819</lpage><pub-id pub-id-type="pmid">18634151</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeRoy</surname><given-names>EC</given-names></name><name><surname>Black</surname><given-names>C</given-names></name><name><surname>Fleischmajer</surname><given-names>R</given-names></name><name><surname>Jablonska</surname><given-names>S</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name><name><surname>Medsger</surname><given-names>TA</given-names><suffix>Jr</suffix></name><name><surname>Rowell</surname><given-names>N</given-names></name><name><surname>Wollheim</surname><given-names>F</given-names></name></person-group><article-title>Scleroderma (systemic sclerosis): classification, subsets and pathogenesis</article-title><source>J Rheumatol</source><year>1988</year><volume>15</volume><fpage>202</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">3361530</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><collab>Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee</collab></person-group><article-title>Preliminary criteria for the classification of systemic sclerosis (scleroderma)</article-title><source>Arthritis Rheum</source><year>1980</year><volume>23</volume><fpage>581</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">7378088</pub-id><pub-id pub-id-type="doi">10.1002/art.1780230510</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garnier</surname><given-names>S</given-names></name><name><surname>Dieude</surname><given-names>P</given-names></name><name><surname>Michou</surname><given-names>L</given-names></name><name><surname>Barbet</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>A</given-names></name><name><surname>Lasbleiz</surname><given-names>S</given-names></name><name><surname>Bardin</surname><given-names>T</given-names></name><name><surname>Prum</surname><given-names>B</given-names></name><name><surname>Cornelis</surname><given-names>F</given-names></name></person-group><article-title>IRF5 rs2004640-T allele, the new genetic factor for systemic lupus erythematosus, is not associated with rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><fpage>828</fpage><lpage>831</lpage><pub-id pub-id-type="pmid">17158136</pub-id><pub-id pub-id-type="doi">10.1136/ard.2006.061390</pub-id></citation></ref></ref-list></back></article> 